Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report

Yukinori Ozaki1,3*, Junichi Shindoh2,3, Yuji Miura1, Hiromichi Nakajima1, Ryosuke Oki1, Miyuki Uchiyama1, Jun Masuda1, Keiichi Kinowaki4, Chihiro Kondoh1, Yuko Tanabe1, Tsuyoshi Tanaka5, Shusuke Haruta5, Masaki Ueno5, Shigehisa Kitano6, Takeshi Fujii4, Harushi Udagawa5 and Toshimi Takano1

Abstract

Background: Pseudoprogression refers to a specific pattern of response sometimes observed in malignant melanoma patients receiving treatment with immune-checkpoint inhibitors. Although cases with pseudoprogression documented once have been reported previously, there have been no case reports yet of pseudoprogression events documented twice during treatment.

Case presentation: A 55-year-old man underwent surgery for locally advanced esophageal malignant melanoma and received postoperative adjuvant interferon therapy. However, he presented with multiple liver and bone metastases at 6 months after the surgery, and was initiated on treatment with nivolumab 2 mg/kg every 3 weeks as the first-line treatment for recurrent disease. Follow-up computed tomography revealed that the liver metastases initially increased transiently in size, but eventually regressed. However, while the liver metastases continued to shrink, a new peritoneal nodule emerged, that also subsequently shrunk during the course of treatment with nivolumab. With only grade 1 pruritus, the patient continues to be on nivolumab treatment at 15 months after the induction therapy, with no progression observed after the second episode of pseudoprogression in the liver and peritoneal nodule.

Conclusions: We present the case of a patient with metastatic malignant melanoma who showed the unique response pattern of serial pseudoprogression during treatment with nivolumab. This case serves to highlight the fact that development of a new lesion may not always signify failure of disease control during treatment with nivolumab.

Keywords: Esophageal malignant melanoma, Nivolumab, Pseudoprogression, Serial

Background

The global incidence of malignant melanoma continues to rise, and unresectable or metastatic melanoma has a poor prognosis, with a reported median survival time of 6–8 months [1–4]. Currently, immunotherapy is the standard therapy for unresectable or metastatic melanoma, and the prognosis of patients with cutaneous metastatic melanoma has improved. Treatment with ipilimumab, an antibody directed against cytotoxic T-lymphocyte antigen-4, has been demonstrated to yield long-term survival in approximately 20% of patients with advanced melanoma [5, 6]. Nivolumab is a fully humanized IgG4 programmed death 1 (PD-1) immune-checkpoint inhibitor antibody, and PD-1 is expressed on antigen-stimulated T cells and tumor cells. Interaction of PD-1 with its ligands inhibits the antitumor activity of the cytotoxic T cells. Nivolumab blocks the interaction between the PD-1 receptor and the programmed death ligands, PD-L1 and PD-L2, and disrupts the negative signal that regulates T-cell activation and proliferation. Nivolumab treatment has been shown to yield a more favorable survival benefit in previously untreated...
patients with metastatic melanoma not harboring a BRAF mutation as compared to dacarbazine, and it has been approved in Japan for the treatment of unresectable or metastatic melanoma [7]. According to a previous report, a durable response was achieved with nivolumab in approximately 40% of patients with cutaneous metastatic melanoma [8].

Mucosal melanoma is rare, accounting for 2% or less of all cases of melanoma, and the prognosis of mucosal metastatic melanoma is poor, with a 5-year survival rate of less than that reported for cutaneous or uveal melanoma [9–11]. It has also been reported that mucosal melanoma is an aggressive subtype of melanoma that is resistant to immune checkpoint inhibitors, and that patients with this disease show lower response rates to treatment and shorter survival [12].

With immunotherapy becoming increasingly easily available to patients, a major problem that has arisen is the lack of an accurate method yet to determine the clinical efficacy of immunomodulatory drugs. Recently, immune-related patterns of response, which cannot be evaluated by the Response Evaluation Criteria In Solid Tumors (RECIST) have been reported in some studies. According to one study, 4% of patients with metastatic melanoma receiving treatment with nivolumab experienced pseudoprogression [13]. Another study classified pseudoprogression into early and delayed pseudoprogression [14]. Nevertheless, the precise details of the patterns of response to immunotherapy remain unclear. Herein, we report the first case that experienced pseudoprogression twice in a patient with metastatic malignant melanoma, who responded to treatment with nivolumab for over 1 year.

**Case presentation**

A 55-year-old previously healthy man was detected as having an abnormal endoscopic finding in an organized gastric cancer screening examination conducted in July 2014. He was afebrile and other vital signs were normal. Physical examination revealed no abnormalities. Fiberoptic gastrointestinal endoscopy showed a 20-mm black elevated lesion in the middle-third of the intrathoracic esophagus. Enhanced computed tomography (CT) revealed nodular wall thickening measuring 15 × 10 mm in size in the middle-third of the intrathoracic esophagus, with no significant lymph node or distant metastasis. Esophageal biopsy was performed and showed proliferation of large round tumor cells and melanophages. Immunohistochemically, these round cells were diffusely positive for human melanin black 45 (HMB45) (diluted 1/10 dilution; Leica, Wetzlar, Germany) and melan A (1/1000 dilution; Thermo Fisher Scientific, Waltham, MA) and partly positive for S-100 protein (1/1000 dilution; Dako, Glostrup, Denmark). There were no expression of BRAF V600E (1/500 dilution; Spring Bioscience, Pleasanton, CA, USA) in tumor cells, and Ki67 (1/1 dilution; Roche, Basel, Switzerland) labelling index of them was 20%. On the basis of these findings, the patient was diagnosed as an esophageal malignant melanoma, clinical T4aN0M0 (stage IVA, UICC, 7th Edition) and was treated in August 2014 by video-assisted thoracic esophagectomy, proximal gastrectomy and 3-field lymph node dissection with ileocolic reconstruction. Macroscopically, the tumor was an irregular elevated black mass of 60 × 25 mm in size that was consistent with the endoscopic findings (Fig. 1a). A microscopic examination demonstrated that the tumor was located in the submucosal lesion and that there were solid proliferation of eosinophilic tumor cells without tubular or papillary structures (Fig. 1b and c). Tumor cells had large round nuclear and melanin pigments were sometimes found in the cytoplasm of tumor cells. Immunohistochemical staining for HMB45 and melan A was positive in tumor cells as with the biopsy specimen (Fig. 1d). Based on these morphological features and immunohistochemical findings, the tumor was diagnosed as a malignant melanoma in the esophagus with T3 invasion, node-positive (3/100), and the disease stage was classified as pT3N1M0 stage III (UICC, 7th Edition). Immunohistochemically, few numbers of cells were positive for CD8 (1/1 dilution; Roche) (Fig. 1e) and PD-L1/CD274 (clone SP142, 1/50 dilution; Spring Bioscience) expression was <1% in tumor-infiltrating immune cells and tumor cells (Fig. 1f).

Although the patient received postoperative adjuvant interferon treatment, a follow-up CT obtained at 6 months after the surgery revealed multiple liver metastases (Fig. 2a). Positron emission tomography (PET)-CT revealed multiple bone metastases, although the patient had no symptoms. The physical examination and blood test findings were normal, except for elevation of the serum lactate dehydrogenase (LDH) level to 711 IU/L. The patient was diagnosed as having recurrent malignant melanoma with liver and bone metastases, and was started on treatment with nivolumab at 2 mg/kg every 3 weeks as the first-line treatment for the recurrent disease, and denosumab as treatment for the bone metastases in February 2015. The liver metastases showed an initial transient increase in size (+119%) in the CT obtained at the 3-month assessment (Fig. 2b), whereas at the 5-month assessment, CT showed shrinkage of the liver metastases with a change of their density (Fig. 2c), fulfilling the definition of early pseudoprogression. While the liver metastases continued to shrink (Fig. 2d and e), a new peritoneal nodule emerged in the abdomen that was detected in the CT obtained at the 8-month assessment (Fig. 3a-d). The peritoneal nodule was 44 × 21 mm in size (Fig. 3d), whereas at the 12-month assessment, the nodule was found to have regressed (Fig. 3e) (delayed pseudoprogression). The changes in the largest diameter of the tumor lesions...
are shown in Fig. 4. No tumor recurrence or progression has been observed after the second episode of pseudoprogression in the liver, peritoneal nodule and bone. Blood tests showed transient elevation of the serum LDH to 1351 IU/L at 1 month after the initiation of nivolumab treatment, with the levels returning to normal range by 4 months after the start of treatment. During the treatment, the absolute number of lymphocyte tended to increase and that of monocyte was stable, resulting the elevation of the ratio of lymphocyte/monocyte. Grade 1 pruritus was the only adverse event observed. No diarrhea or signs of intra-peritoneal infection were observed during the treatment. At the time of the follow-up in May 2016, he had received nivolumab treatment for 15 months and had shown, until then, no further signs of clinical disease progression.

Discussion and conclusions
Here we report the patient presenting recurrent malignant melanoma with liver and bone metastases who received nivolumab treatment. During the treatment, the liver metastases showed an initial transient increase and subsequent shrinkage, which meets with the criteria of early pseudoprogression. After the pseudoprogression in liver metastases, a new peritoneal lesion emerged and it regressed thereafter. Although pseudoprogression caused by nivolumab treatment is reported in about 4% of patients with metastatic melanoma [13], this unique serial response pattern has never been reported so far.

Immunotherapeutic agents, such as nivolumab, ipilimumab and pembrolizumab, are being tested as novel anticancer therapies for many types of solid tumors. Because of the novel mechanisms of action, immune-related patterns of response that cannot be evaluated by conventional RECIST have been reported, and the landscape of the patterns of response in solid tumors treated with immunotherapeutic agents remains unclear. One study classified pseudoprogression into early and delayed pseudoprogression [14]. Early pseudoprogression is defined as a ≥25% increase of the tumor burden or a new lesion detected at imaging assessment at 12 weeks, which, however, is not confirmed as progressive disease according to Immune-related Response Criteria (irRC) at the next assessment. Delayed pseudoprogression is defined as a ≥25% increase of the tumor burden or a
new lesion at any imaging assessment performed after the first imaging assessment, which is not confirmed as progressive disease according to the irRC at the subsequent imaging assessment. Another study showed that 8.9% of metastatic melanoma patients treated with ipilimumab experienced pseudoprogression, classified as early pseudoprogression (4.6%) or delayed pseudoprogression (4.3%) [15]. In the KEYNOTE-001 melanoma expansion cohorts, early pseudoprogression was observed in 4.6% patients and delayed pseudoprogression in 2.8% patients who had received treatment with pembrolizumab [14]. However, there has been no report on serial patterns of pseudoprogression observed in one patient with malignant melanoma. Development of new lesions after early pseudoprogression could be evaluated as actual disease progression and mistakenly lead to discontinuation of treatment in patients who

![Fig. 2](Liver metastases from malignant melanoma which showed early pseudoprogression during treatment with nivolumab. a Liver metastases (arrowhead indicates the target lesion: 31 mm) before the start of treatment with nivolumab. b CT at the 3-month assessment: the liver metastases had increased in size (target lesion: 63 mm). c CT at the 5-month assessment: the liver metastases had shrunk (target lesion: 31 mm), associated with a change of the density. d CT at the 8-month assessment: the target lesion was 20 mm in diameter. e CT at the 12-month assessment: the target lesion was 13 mm in diameter.)

![Fig. 3](Peritoneal nodule emerged in the abdomen. a, b, c No tumor lesion was detected before the start of treatment with nivolumab (a), at the 3-month (b) and 5-month assessment (c). d At the 8-month assessment, a new peritoneal nodule was detected in the abdomen (arrowhead). The nodule measured 44 X 21 mm in size. e At the 12-month assessment, the nodule had decreased in size and an opacity could be seen next to the intestinal tract.)
would potentially benefit from treatment continuation like present case.

The treatment response pattern of pseudoprogression is sometimes encountered in patients with melanoma receiving immunotherapy. However, the mechanism of pseudoprogression is not yet clearly understood. Therefore, it is especially difficult for us to explain the mechanism of pseudoprogression events occurring twice in the current patient. Different mechanisms could have been operative between the early pseudoprogression and delayed pseudoprogression in this case. The early pseudoprogression was detected in the liver, where metastases were already present before the treatment was started. This response in the liver could possibly be explained by inflammatory cell infiltration or necrosis, as suggested previously [14]. On the other hand, we would like to speculate on some possible mechanisms underlying the delayed pseudoprogression. First, the heterogeneity of the immune microenvironments between the liver metastases and peritoneal nodules might have been responsible for the pseudoprogression events detected at different time-points. Several studies have reported the existence of a correlation between the clinical response and expression of PD-L1 on the tumor cells [16]. Immunohistochemically, the resected primary esophageal tumor showed no PD-L1 expression (<1%) in tumor-infiltrating immune cells and tumor cells, and it suggests no PD-L1 expression originally in the peritoneal metastasis. After the tumor response in liver metastases, the PD-L1 expression in the peritoneal metastasis might have been up-regulated by increasing infiltration of CD8-positive T cells [17], which could have led to the delayed pseudoprogression documented in our case. Second, differences in the tumor growth rate could have led to the time lag between the two pseudoprogression events. The slower tumor growth of peritoneal metastasis than the liver metastases could have caused a time lag in the development of immune evasion. However, we could not prove the validity of our hypothesis by histopathology in this patient, because we could not obtain the patient’s consent to perform tumor biopsy after progression.

The presence of tumor-infiltrating lymphocytes (TILs) is an important factor in the immune responses of a tumor [18]. Although we did not quantitate the TILs histopathologically in this patient, we analyzed the
leukocyte counts in the peripheral blood during the treatment. Some retrospective studies reported that the numbers of lymphocytes, mononuclear myeloid-derived suppressor cells (MDSCs) and neutrophils in peripheral blood were associated with clinical outcome [19–22]. As shown in Fig. 4, during the treatment, the lymphocyte/monocyte ratio was elevated in this case. Increase in the number of lymphocytes in the blood suggests activation of the immune system. On the other hand, a stable number of monocytes indicates the stable presence of MDSCs, which inhibit cytotoxic T lymphocyte activity [20]. An increase in the count of MDSCs has been reported to be associated with tumor progression, poorer outcomes, and decreased effectiveness of immunotherapeutic strategies [19, 23], while a stable number of monocytes appears to be associated with good outcomes. Therefore, the lymphocyte/monocyte ratio in our patient suggests continued activation of the antitumor immune responses, which could have led to the serial pseudoprogression events.

According to the irRC, immune-related progressive disease is defined as “at least 25% increase in tumor burden compared with nadir (at any single time point) in two consecutive observations at least 4 weeks apart” [15]. There is no report or definition about serial pseudoprogression, and the emergence of a new lesion after early pseudoprogression is likely to be diagnosed as progressive disease. Our experience indicates that the development of a new lesion after early pseudoprogression might not always signify failure of disease control during treatment with nivolumab. Further accumulation of data is required to better understand the immune-related responses and for the confirmation of disease progression. In conclusion, we report a case of metastatic malignant melanoma that showed the unique response pattern of serial pseudoprogression during the course treatment with nivolumab. Development of a new lesion detected radiographically after early pseudoprogression might not always signify failure of disease control. More data are needed to understand immune-related responses to immunotherapy and for the confirmation of disease progression.

Abbreviations
CT: computed tomography; HMB45: human melanin black 45; irRC: immune-related Response Criteria; LDH: lactate dehydrogenase; MDSCs: mononuclear myeloid-derived suppressor cells; PD-1: programmed death 1; PET: positron emission tomography; RECIST: Response Evaluation Criteria In Solid Tumors; TILs: tumor-infiltrating lymphocytes; UICC: Union International Contra Cancrum

Acknowledgements
This work was supported by clinical research coordinators; Ms. Nonogaki, Ms. Sato, Ms. Ozeki, Ms. Uruma, Ms. Takeshita, Ms. Igaki and Ms. Akiyama.

Ethical approval and consent for publication
Not applicable

Funding
This study had no funding.

Availability of data and materials
The data used and/or analysed of this patient are available from the corresponding author on reasonable request.

Authors’ contributions
YO, JS, YM and SK analyzed and interpreted the data as major contributors in writing the manuscript. HN, RO, MU, JM, KK, CK, YT and TsT. contributed to the interpretation of the data. SH, MU, TR have made contribution to acquisition and analysis of data and HU and ToT. have been involved in drafting and revising this manuscript. All authors read, provided feedback and approved the final manuscript.

Consent for publication
Written informed consent for publication was obtained from the patient of this case report.

Competing interests
Yuiji Miura: Honoraria from Novartis and Kyowa Hakko Kirin. The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo 105-8470, Japan. 2Hepatobiliary-pancreatic Surgery Division, Department of Digestive Surgery, Toranomon Hospital, Tokyo, Japan. 3Okinaka Memorial Institute for Medical Disease, Tokyo, Japan. 4Department of Pathology, Toranomon Hospital, Tokyo, Japan. 5Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan. 6Department of Experimental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Tsukiji, Japan.

Received: 8 February 2017 Accepted: 14 November 2017
Published online: 21 November 2017

References
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
2. Ghosh P, Chin L. Genetics and genomics of melanoma. Expert Rev Dermatol. 2009;4:131.
3. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Wicklund JM, Atkins MB, Thompson JA, Colt DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Miettinen A. Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer melanoma staging system. J Clin Oncol. 2001;19:3622–34.
4. Barth A, Waneck LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193–201.
5. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–82.
6. Schadendorf D, Hodi FS, Robert C, Weber JS, Bruxner T, Hamid O, Robert C, Sznol M, Atkinson V, Ascierto PA. Nivolumab in previously untreated melanoma with Ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017;35:226–35.
9. Ahmad SS, Qian W, Ellis S, Mason E, Khattak MA, Gupta A, Shaw H, Quinton A, Kovarikova J, Thillai K, Rao A, Board R, Nobes J, Dalgleish A, Grumett S, Maraveyas A, Danson S, Talbot T, Harries M, Marples M, Plummer R, Kumar S, Nathan P, Middleton MR, Lorigan P, Wheater M, Ottensmeier CH, Corrie PG. Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Res. 2015;25:432–42.

10. Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. J Clin Exp Pathol. 2012;5:739–53.

11. DeMatos P, Tyler DS, Seigler HF. Malignant melanoma of the mucous membranes: a review of 119 cases. Ann Surg Oncol. 1998;5:333–42.

12. Wang X, Si L, Guo J. Treatment algorithm of metastatic mucosal melanoma. Chin Oncol. 2014;3:20–29.

13. Topalian SL, Sznol M, McDermott DF, Krueger KM, Carvajal RD, Sharman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Lipson EI, Puzanov I, Smith DC, Taube JM, Wigginton JM, Goggins M, Gupta A, Pardoll DM, Sosman JA, Hodi FS. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30.

14. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Riaz A, Roberts C, Hersey P, Dronca R, Joseph R, Hille D, Xu D, Li XN, Yang A, Lorigan P, Haining W, Gadgeel S, Patel J, Jagsi R, Sherry K, Wolchok JD, Chiarini E, Hodi FS. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510–7.

15. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohmack O, Nichol G, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. J Natl Cancer Inst. 2009;101:7412–20.

16. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Meyers B, Hoeller C, Khushalani N, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Aisertio PA, Mohr P, Chmielowski B, Bryne A, Svane IM, Grob JJ, Kecdhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma progressing after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–84.

17. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116.

18. Teng MW, Ngiiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75:2139–45.

19. Kitano S, Postow MA, Ziegler CG, Kuk D, Panagias KS, Cortez C, Rasalan T, Adamow M, Yuan J, Wong P, Altan-Bonnet G, Wolchok JD, Leskin AM. Computational algorithm-driven evaluation of monocyte-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res. 2014;2:812–21.

20. Vallow M, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125:3356–64.

21. Nakamura Y, Kitano S, Takahashi A, Tsutsuimida A, Namikawa K, Tanese K, Abe T, Funakoshi T, Yamamoto N, Arnagai M, Yamazaki N, Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget. 2016;7(47):77404–15.

22. Martens A, Wistuba-Hampecht K, Yuan J, Postow MA, Wong P, Capone M, Madonna G, Khammani A, Schilling B, Sucker A, Schadendorf D, Marcus P, Dreno B, Ascierto PA, Wolchok JD, Pesalacca G, Garbe C, Wiede B. Increases in absolute lymphocytes and circulating CD8+ and CD4+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. Clin Cancer Res. 2016;22:4848–58.

23. Tada K, Kitano S, Shojo H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takehisa A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T, Pretreatment immune status correlates with progression-free survival in chemotherapy-treated metastatic colorectal cancer patients. Cancer Immunol Res. 2016;4:592–9.